As Taiwan strengthens its leadership in healthcare innovation, Moderna is deepening its commitment — advancing mRNA science, partnerships, and long-term capabilities that help shape the future of medicine.
At the center of this effort is Wenchi Liu, General Manager of Moderna Taiwan, whose leadership reflects more than two decades of experience across the healthcare sector. Known for her patient-first philosophy and strong execution mindset, Liu is translating global advances in healthcare into tangible community impact.
“My role is to bridge global innovation with local needs,” Liu explains. “What matters most is whether patients here in Taiwan can benefit from the latest scientific advancements in a timely and meaningful way.”
One of the most significant developments in this mission is the continued advancement of mRNA science, which is enabling new approaches to address changing healthcare needs.
Over the past few years, Moderna has worked with the Taiwan government to support healthcare initiatives, particularly for vulnerable populations following the Covid-19 pandemic.
“Moderna will continue to collaborate with the government and healthcare partners to strengthen preparedness for ongoing health challenges,” Liu says.
Positioning Taiwan as a priority mar-ket is a deliberate strategic decision. With its advanced healthcare infrastructure, strong regulatory environment, and proactive health policies, Taiwan plays a critical role in Moderna’s Asia-Pacific vision.
“Taiwan has consistently demonstrated leadership in public health and preparedness,” Liu notes. “That is why we see Taiwan not just as a market, but as a key partner in driving innovation and setting an example for the region.”
Liu is also focused on building a sustainable mRNA research network in Taiwan. This includes strengthening collaboration with academic institutions, healthcare providers, and research organizations to support scientific progress and local capability building.
“Innovation does not happen in isolation,” she says. “We are committed to working closely with partners in Taiwan to build an ecosystem where research, talent, and technology can thrive together.”
These initiatives are closely linked to strengthening health security. By combining Moderna’s global expertise with Taiwan’s local strengths, the company aims to contribute to a more resilient healthcare system — better prepared for major public health risks.
“Moderna’s mRNA scientific expertise is critical in responding to health threats,” Liu emphasizes. “Preparedness is about building the right infrastructure, partnerships, and capabilities in advance so that we are ready — no matter what comes next.”
She adds that globally, several governments — including the UK, Australia, Canada, and Mexico — are exploring the role of mRNA science as part of their pandemic preparedness strategies, reflecting growing recognition of its potential in strengthening long-term healthcare resilience.
Beyond strategy, a defining aspect of Liu’s leadership is her focus on people. She has prioritized building high-performing local teams that are empowered to take ownership and drive execution excellence. By fostering a culture of collaboration, accountability, and purpose, she is ensuring that Moderna Taiwan is positioned for sustainable growth. “I’m truly grateful for the strength of our local team here in Taiwan, and for the close collaboration we have with our regional and global colleagues, which enables us to move faster and deliver better outcomes for patients,” she adds.
Looking ahead, Liu sees investment in next-generation talent as essential to unlocking the full potential of mRNA science. Moderna is supporting initiatives that promote scientific exchange, education, and the development of the next generation of innovators in Taiwan.
“The future of healthcare will depend on the next generation of scientists, researchers, and leaders,” she says. “We want to support that journey by creating opportunities for learning, collaboration, and innovation.”
For Liu, leadership is ultimately about delivering impact beyond business outcomes. It is about contributing to society, strengthening health systems, and improving lives.
“Innovation is only meaningful when it reaches people,” she reflects. “Our ambition is to build something lasting —an ecosystem that continues to create value for patients and society for years to come.”
As Moderna advances its next chapter in Taiwan, Liu’s leadership underscores a clear vision: combining global innovation with local commitment to shape a healthier, more resilient future.
